# AxoGen

Type: Company (AXGN)

Source: GetYourBrief — https://getyourbrief.com/entity/axogen
Canonical HTML page: https://getyourbrief.com/entity/axogen

## Recent coverage (6 stories, network-wide)

### DAFNA Capital Trims Axogen Stake by $6.5M Following 71% Stock Surge
2026-03-22 04:28:38 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately 265,456 shares during the fourth quarter of 2025, a move valued at $6.53 million. Despite the trim, the hedge fund maintains a significant $15.6 million stake in the nerve-repair specialist, which has seen its stock price climb 71% over the past year.
Full story: https://getfinancebrief.com/story/dafna-capital-axogen-trim-analysis

### DAFNA Capital Trims Axogen Stake Following 71% Rally and 20% Revenue Growth
2026-03-22 04:25:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Full story: https://getbiobrief.com/story/dafna-capital-trims-axogen-stake-71-surge

### DAFNA Capital Trims Axogen Stake Amid 71% Stock Surge and Strong Revenue Growth
2026-03-22 04:25:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, following a period of significant outperformance. Despite the trim, Axogen remains a core holding for the fund as the medical device maker continues to capitalize on its 20% revenue growth and dominant position in the peripheral nerve repair market.
Full story: https://gethealthbrief.com/story/dafna-capital-axogen-trim-analysis

### AxoGen Surges as Wells Fargo Issues Rare 'Strong-Buy' Rating Upgrade
2026-02-21 01:12:47 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AxoGen (NASDAQ: AXGN) has received a major boost from Wall Street as Wells Fargo upgraded the nerve-repair specialist to a 'Strong-Buy' rating. The upgrade follows a significant price target hike from Jefferies, signaling a robust consensus on the company's growth potential in the medical technology sector.
Full story: https://getfinancebrief.com/story/axogen-axgn-wells-fargo-strong-buy-upgrade

### Wells Fargo Upgrades AxoGen to Strong-Buy as Nerve Repair Market Gains Momentum
2026-02-21 01:12:15 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo has upgraded AxoGen (NASDAQ: AXGN) to a 'Strong-Buy' rating, reflecting growing institutional confidence in the company's leadership in peripheral nerve repair. The upgrade follows a significant price target increase from Jefferies and a reaffirmed 'Market Outperform' rating from Citigroup.
Full story: https://getbiobrief.com/story/axogen-wells-fargo-upgrade-nerve-repair-market

### Wells Fargo Upgrades AxoGen to Strong-Buy as Nerve Repair Market Gains Momentum
2026-02-21 01:11:42 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AxoGen (NASDAQ: AXGN) has received a significant rating upgrade to "Strong-Buy" from Wells Fargo, signaling robust institutional confidence in the peripheral nerve repair specialist. This move, coupled with price target hikes from Jefferies and positive outlooks from Citigroup, underscores a bullish sentiment for the company's clinical and commercial trajectory.
Full story: https://gethealthbrief.com/story/axogen-wells-fargo-strong-buy-upgrade

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.